Unlike the PDE (Permissible Daily Exposure), the ADI considers oral intake only, and might therefore be the better choice for oral-only health products or food related products.
The ADI concept can be understood as a measure to indicate the toxicity from long-term exposure to repeated ingestion of chemical compounds (present and/or added), as opposed to acute toxicity.
The No-Observed-Adverse-Effect Level, the amount of a substance that shows no toxic effects, is determined by performing studies with several doses including high doses. In the case of several studies on different effects, the lowest NOAEL is usually taken.
The determination of an ADI is to verify the safety of an (orally ingestable) compound and the provision of high quality pharmaceutical products.
As one of the most successful health science consultation providers on the market, our team of consultants has the experience and know-how to provide quick, reliable, and specific services with regard to ADI or NOAEL determination as well as any other pharmaceutical and/or biotechnological request.
Please feel free to contact us at any given time, to find out more about IASON consulting and our provided services throughout the health care industry.